Agavni Mesropian

PhD student @Idibaps (Barcelona), MSc Translational Medicine, BSc Biomedical Sciences

[IDIBAPS @idibaps]

@NatureGenet @hospitalclinic @AMesropi 🆕Descubren qué tumores hepáticos con mutaciones en β-catenina responden a la inmunoterapia

El estudio, con participación del #CLÍNIC-#IDIBAPS, publicado en @NatureGenet, abre la puerta a estrategias de medicina personalizada

👉https://t.co/yhg5dEQ3Rj

[IDIBAPS @idibaps]

@NatureGenet @hospitalclinic @AMesropi 🆕Descobreixen quins tumors hepàtics amb mutacions en β-catenina responen a la immunoteràpia

L'estudi, amb participació del #CLÍNIC-#IDIBAPS, publicat a @NatureGenet, obre la porta a estratègies de medicina personalitzada

👉https://t.co/CIk1kcsKd7

[IDIBAPS @idibaps]

🆕Researchers discover which liver tumors with β-catenin mutations respond to immunotherapy

The study, with the participation of #CLÍNIC-#IDIBAPS, published in @NatureGenet, opens the door to personalized medicine strategies

👉https://t.co/xsAZUB1jQ6

[Ezequiel Mauro @ezemauro_ok]

🤖 AI in HCC pathology @JHEP_Reports
Deep learning model predicts:
✅ Prognosis-related molecular classes
✅ Microvascular invasion
➡️ From routine H&E slides, with clinical implications for risk stratification @AMesropi @AEEHLiver @EASLnews @ILCAnews
https://t.co/C9OS2bdGEl

[Ezequiel Mauro @ezemauro_ok]

4/ 2 posters presentation with our amazing teams!
🧠AI-driven prediction of biology-based risk and vascular invasion in HCC
🧬Spatial transcriptomics reveals immune features of response vs resistance to Atezo-Bev in advanced HCC
@EASLnews @THRIVE_LiverCan @IDIBAPS @AMesropi

[EASLnews @EASLnews]

Meet @THRIVE_LiverCan representatives at #EASLCongress next week and learn more about the project!

When: Thursday 8 May, 10:00-10:30
Where: Track Hub 3, Liver Tumours

More information: https://t.co/BCpqarZbWm

[THRIVE Liver Cancer EU Project @THRIVE_LiverCan]

🎉 Excited to be part of #EASLCongress 2025! We’re sharing our latest research across multiple sessions. Check out all our presentations below ⬇️ #Livertwitter

[IDIBAPS @idibaps]

🆕Identified the molecular characteristics associated with responses or resistance to treatment with immunotherapy in patients with advanced liver cancer

The findings open the door to designing new and more effective therapeutic strategies

👉https://t.co/fugmK1At5P

[IDIBAPS @idibaps]

🟣Avui, en el Dia de la Dona i la Nena en la Ciència, les dones de l'#IDIBAPS ens hem ajuntat per aconseguir una imatge molt especial...

3 nenes, amb la seva mirada única, capturen el poder dels referents femenins. Som el que veiem!📸
#WomenInScience #11F2025 @hospitalclinic

[THRIVE Liver Cancer EU Project @THRIVE_LiverCan]

📸 Family picture of the First European Cluster on Understanding Tumour Host Interactions meeting! 🤝 Excited to collaborate with other consortia tackling tumor-host interactions across various cancers. Together, we drive research forward! 🌍 #CancerResearch

[RTVE Notícies @rtvenoticies]

🏥 Un estudi internacional liderat pel @idibaps millora el tractament del càncer de fetge més freqüent | @elenasantosc

[IDIBAPS @idibaps]

🆕An international study led by #CLÍNIC-#IDIBAPS published today in @TheLancet presents a drug combination that improves the prognosis of liver cancer

The first improvement in 20 years

👉https://t.co/0BOdHZYMBG

@hospitalclinic @‌HCC_HUNTER @THRIVE_LiverCan

[Agavni Mesropian @AMesropi]

Check out our recent paper in JHep Reports!

[JHEP Reports @JHEP_Reports]

❕Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in #HCC

🔓#OpenAccess at👉https://t.co/jlWH7LTxsp

#LiverTwitter
@mpiquegili
@CarmenAO92
@AMesropi

[THRIVE Liver Cancer EU Project @THRIVE_LiverCan]

This week, #THRIVE will be at the #ENASymp24 in Barcelona, sharing our latest research!

📅 Wed, Oct 23 | 12:00-19:00:
🔷Poster 110: New targeted therapies in HB (@UBalaseviciut)
🔷Poster 76: Enhancing lenva+aPD1 in HCC (@AMesropi)

https://t.co/MIaewdd0As

@idibaps @EuropeLiver

[Jeroen Dekervel @JDekervel]

Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC - JHEP Reports https://t.co/EYi6b5Yb7B

[THRIVE Liver Cancer EU Project @THRIVE_LiverCan]

Great brainstorming at the first #THRIVE working meeting in Tavertet!

Two wonderful days filled with new ideas for putting our plans into action, achieving our goals and advancing collaborative projects within the consortium.

#LiverTwitter #CancerResearch #EU

[THRIVE Liver Cancer EU Project @THRIVE_LiverCan]

The European Union launches the THRIVE project, coordinated by Prof. Josep M. Llovet, to improve the prognosis of children and adults with #livercancer.

More information about the project at: https://t.co/zWgcLe2DXX

[Agavni Mesropian @AMesropi]

Thrilled to be at the #AACR23 congress! Excited about these days surrounded by top notch cancer research in Orlando. @AACR

[Laura Torrens @LauraTorrensF]

Watch the video summary of our paper "Inflamed and non-inflamed classes of HCC: a revised immunogenic classification", led by @CMontironi and Florian Castet @idibaps @MountSinaiLiver

[MountSinaiLiver @MountSinaiLiver]

🥳💙❤️The 2022 Mount Sinai Annual Liver Cancer Conference was a success. Thank you to everyone that attended and presented.
#LiverCancer #LiverCancerAwareness #Cancer #CancerAwareness #liverdisease #liverhealth #HCC #cholangiocarcinoma #WeFindAWay